Wall Street firms are increasingly optimistic about Datadog's (DDOG) trajectory toward 2026, with Stifel upgrading the stock to Buy and highlighting strong Q4 expectations, even as the company navigates sector-wide pricing and competitive pressures.
Investment firms Stifel and Northland have raised their price targets on Ondas Holdings (ONDS), following a virtual investor day where management outlined an ambitious growth roadmap, highlighting the company's unique position in military drones and private wireless networks.
Oracle shares face continued pressure over debt and AI infrastructure costs, but Guggenheim's bullish $400 price target suggests potential for a multi-year rebound if execution risks are managed.
As the cryptocurrency market grapples with sustained selling pressure, a new analysis highlights significant vulnerabilities for two of the most recognizable digital assets, XRP and Dogecoin, projecting potential losses exceeding 50% in the coming year.
While the small-cap index is a hunting ground for growth, some constituents face significant headwinds. We examine three companies where valuation and market dynamics warrant a cautious approach.
AMD stock fell sharply Friday following a report of potential delays to its next-generation MI450 AI chip, sparking a debate over whether the sell-off is an overreaction or a sign of deeper valuation concerns.
Amidst a market rally driven by a handful of tech giants, certain volatile stocks present outsized risks. We examine three names where valuation concerns and sector headwinds warrant a cautious approach.
While lofty price targets can signal opportunity, a closer look reveals that not all consensus forecasts are created equal. We examine one company poised to deliver and two where investor caution may be warranted.
Citizens JMP reaffirms its bullish stance on Salesforce, citing the explosive growth of its AI platform Agentforce and strong enterprise adoption as key catalysts for sustained outperformance.
USA Rare Earth Inc. (NASDAQ: USAR) sees its price target significantly raised by Canaccord Genuity and Benchmark following a landmark $1.6 billion commitment from the U.S. CHIPS Program, accelerating its plans to build a domestic rare earth supply chain.
Despite a trimmed price target from B. Riley, WhiteFiber Inc. (WYFI) secures a pivotal 10-year colocation agreement expected to generate $865 million, spotlighting its role in the expanding AI infrastructure sector.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
While mid-cap companies often represent a sweet spot between growth and stability, heightened competition and shifting market dynamics are putting pressure on some notable names. Here’s a closer look at three stocks where caution may be warranted.
Barclays' upgrade of PTC Therapeutics to Overweight has spotlighted the biotech firm's valuation, with shares showing strong momentum but questions lingering over its path to profitability and reliance on a narrow drug portfolio.
While Exelon's recent earnings beat expectations, the utility giant continues to face investor skepticism over its long-term growth trajectory. Wall Street maintains a guarded optimism, but the stock's performance tells a more nuanced story.
While rising crude prices have lifted Occidental Petroleum's stock recently, a mixed earnings performance and a predominantly 'Hold' rating from Wall Street signal lingering skepticism about its near-term trajectory.
After soaring to unprecedented highs, copper prices have begun to retreat. Goldman Sachs forecasts a more significant market adjustment by mid-2026, driven by potential U.S. tariff policies and a disconnect from fundamental demand.
Morgan Stanley and Barclays have both lowered their price targets for Appalachian Basin natural gas leader Antero Resources (AR), citing revised commodity forecasts. Despite the cuts, Morgan Stanley maintains an 'Overweight' rating, signaling continued confidence in the stock's long-term trajectory.
A revised price target for Invesco Mortgage Capital (IVR) is prompting investors to reassess the mortgage REIT's trajectory amid evolving interest rate expectations and housing market dynamics.
Rosenblatt Securities initiates coverage on Credo Technology with a Neutral rating and a $170 price target, highlighting its strong position in high-speed connectivity for AI infrastructure while flagging competitive pressures. The note follows a more bullish target hike from Barclays earlier in the month.
